Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction rather than comprehensive financial performance.
Material Changes
The filing reports an increase in the shareholding interest of Dr. M. M. Slaoui. This change resulted from the re-investment of a dividend paid to shareholders on January 6, 2011. The transaction involved the purchase of 326 ordinary shares at a price of £12.30 per share on January 12, 2011.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a director's transaction in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: January 12, 2011
- Shareholder: Dr. M. M. Slaoui
- Shares Acquired: 326 Ordinary shares
- Price per Share: £12.30
- Source of Funds: Re-investment of dividend paid on January 6, 2011
- Reporting Date: January 17, 2011